RESUMEN
A renewed interest in the use of ß-blockers for neurodevelopmental disorders has recently resurfaced, notably as an addition to the limited psychopharmacological armamentarium of autism spectrum disorders (ASD). In this clinical perspective, authors decently argue this use could be advantageous and multi-folded for this population.
Asunto(s)
Trastorno del Espectro Autista , Trastorno Autístico , Humanos , Trastorno Autístico/tratamiento farmacológico , Trastorno del Espectro Autista/tratamiento farmacológicoRESUMEN
ABSTRACT: In the aftermath of COVID-19, it sounds equally important, on the part of mental health providers to undertake the onerous duty of promoting resilience, to empower individuals, foster their own natural strengths, and help them incorporate new coping strategies into their everyday lives at this exceptional moment of hardship.
Asunto(s)
Adaptación Psicológica , COVID-19/psicología , Resiliencia Psicológica , COVID-19/epidemiología , Felicidad , Humanos , Pandemias , SARS-CoV-2Asunto(s)
Aripiprazol/administración & dosificación , Clorhidrato de Duloxetina/administración & dosificación , Esquizofrenia/tratamiento farmacológico , Adolescente , Antipsicóticos/administración & dosificación , Dopaminérgicos/administración & dosificación , Quimioterapia Combinada , Humanos , Masculino , Esquizofrenia/fisiopatología , Resultado del TratamientoRESUMEN
Cognitive dysfunction in MDD is more of an endophenotype rather than an epiphenomenon. This sorely remains un face cachee of MDD and largely unimpacted by currently available pharmacological and non-pharmacological interventions. These deficits have been considerably tied to symptoms residua, increased risk of relapse, functional impairment, and, reduced quality of life. Accordingly, targeting cognitive symptoms domain in MDD is unmet clinical desideratum in the journey to functional recovery.